Healthcare resource use in schizophrenia, EuroSC findings

References

• CTI Reviews. Cultural psychology: cram101. 2016. Available from: https://books.google.fr/books?id=po6XRY6CmcoC&printsec=frontcover&hl=fr#v=onepage&q&f=false
   Google Scholar
• Prasad BV. Chronic mental illness and the changing scope of intervention strategies, diagnosis, and treatment. Hershey (PA): IGI Global; 2016.
   Google Scholar
• World Health Organization. Mental health. schizophrenia. [ citedJan2017]. Available from: http://www.who.int/mental_health/management/schizophrenia/en/
   Google Scholar
• Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):1–9 .
   Web of Science ®Google Scholar
• Jablensky A. The diagnostic concept of schizophrenia: its history, evolution, and future prospects. Dialogues Clin Neurosci. 2010;12(3):271–287.
   PubMedGoogle Scholar
• Grohol J. PsychCentral. Schizophrenia usually strikes first in young adults. [ citedMay2017]. Available from: https://psychcentral.com/blog/archives/2013/12/09/schizophrenia-usually-strikes-first-in-young-adults/
   Google Scholar
• National Institutes of Health. National Institute of Mental Health. Schizophrenia. [ citedJan2017]. Available from: https://www.nimh.nih.gov/health/statistics/prevalence/schizophrenia.shtml
   Google Scholar
• Tandon R, Nasrallah H, Keshavan M. Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr Res. 2009;110(1–3):1–23.
   PubMed Web of Science ®Google Scholar
• Samele C, Frew S, Urquía N. Mental health systems in the European Union Member States, Status of Mental Health in Populations and Benefits to be expected from investments into mental health. Jul 2013 cited 2017 Jan. Available from: http://ec.europa.eu/health//sites/health/files/mental_health/docs/europopp_full_en.pdf
   Google Scholar
• OECD/EU. Health at a Glance: Europe. 2016 – State of health in the EU cycle. Paris: OECD Publishing; 2016. Available from: http://dx.doi.org/10.1787/9789264265592-en
   Google Scholar
• Vermeulen B, Lauwers H, Spruytte N, et al. Experiences of family caregivers for persons with severe mental illness: an international exploration. Leuven: LUCAS KU Leuven/EUFAMI; 2015.
   Google Scholar
• Caqueo-Urízar A, Miranda-Castillo C, Lemos Giráldez S, et al. An updated review on burden on caregivers of schizophrenia patients. Psicothema. 2014;26(2):235–243.
   PubMed Web of Science ®Google Scholar
• Awad A, Voruganti L. The burden of schizophrenia on caregivers: a review. Pharmacoeconomics. 2008;26(2):149–162.
   PubMed Web of Science ®Google Scholar
• Bebbington PE, Angermeyer M, Azorin JM, et al. The European Schizophrenia Cohort (EuroSC): a naturalistic prognostic and economic study. Soc Psychiatry Psychiatr Epidemiol. 2005; 40(9):707–717.
   Web of Science ®Google Scholar
• Millier A, Sarlon E, Azorin JM, et al. Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis. BMC Psychiatry. 2011;11:24. doi:  10.1186/1471-244X-11-24
   Web of Science ®Google Scholar
• Bebbington PE, Angermeyer M, Azorin JM, et al. Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. Acta Psychiatr Scand Suppl. 2009;119(438):22–28.
   Google Scholar
• Heider D, Angermeyer MC, Winkler I, et al. A prospective study of Quality of life in schizophrenia in three European countries. Schizophr Res. 2007;93(1–3):194–202.
   Web of Science ®Google Scholar
• Marwaha S, Johnson S, Bebbington P, et al. Correlates of subjective quality of life in people with schizophrenia: findings from the EuroSC study. J Nerv Ment Dis. 2008;196(2):87–94.
   PubMed Web of Science ®Google Scholar
• Marwaha S, Johnson S, Bebbington P, et al. Rates and correlates of employment in people with schizophrenia in the UK, France and Germany. Br J Psychiatry. 2007;191:30–37.
   Web of Science ®Google Scholar
• Schomerus G, Heider D, Angermeyer MC, et al. Residential area and social contacts in schizophrenia. Results from the European Schizophrenia Cohort (EuroSC). Soc Psychiatry Psychiatr Epidemiol. 2007;42(8):617–622.
   PubMed Web of Science ®Google Scholar
• Siegrist K, Millier A, Amri I, et al. Association between social contact frequency and negative symptoms, psychosocial functioning and quality of life in patients with schizophrenia. Psychiatry Res. 2015;230(3):860–866.
   Web of Science ®Google Scholar
• Schomerus G, Heider D, Angermeyer M, et al. Urban residence, victimhood and the appraisal of personal safety in people with schizophrenia: results from the European Schizophrenia Cohort (EuroSC). Psychol Med. 2008;38(4):591–597.
   PubMed Web of Science ®Google Scholar
• Roick C, Heider D, Bebbington P, et al. Burden on caregivers of people with schizophrenia: comparison between Germany and Britain. Br J Psychiatry. 2007;190:333–338.
   Web of Science ®Google Scholar
• Heider D, Bernert S, König HH, et al. Direct medical mental health care costs of schizophrenia in France, Germany and the UK - findings from the European Schizophrenia Cohort (EuroSC). Eur Psychiatry. 2009;24(4):216–224.
   PubMed Web of Science ®Google Scholar
• Sarlon E, Heider D, Millier A, et al. A prospective study of health care resource utilisation and selected costs of schizophrenia in France. BMC Health Serv Res. 2012;12:269–276.
   Web of Science ®Google Scholar
• Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res. 2004;71(1):155–165.
   PubMed Web of Science ®Google Scholar
• Mohr PE, Cheng CM, Claxton K, et al. The heterogeneity of schizophrenia in disease states. Schizophr Res. 2004;71(1):83–95.
   PubMed Web of Science ®Google Scholar
• Thokagevistk K, Millier A, Lenert L, et al. Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations. J Mark Access Health Policy. 2016;4. DOI: 10.3402/jmahp.v4.30725. eCollection 2016.
   Google Scholar
• Einarson TR, Geitona M, Chaidemenos A, et al. Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece. Ann Gen Psychiatry. 2012;11(1):18.
   Web of Science ®Google Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the USA. Cost Eff Resour Alloc. 2009;7:4. DOI: 10.1186/1478-7547-7-4
   Google Scholar
• García-Ruiz AJ, Pérez-Costillas L, Montesinos AC, et al. Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. Health Econ Rev. 2012;2(1):8.
   PubMedGoogle Scholar
• Murphy SM, McDonell MG, McPherson S, et al. An economic evaluation of a contingency-management intervention for stimulant use among community mental health patients with serious mental illness. Drug Alcohol Depend. 2015;153:293–299. doi: 10.1016/j.drugalcdep.2015.05.004.
   Web of Science ®Google Scholar
• Peng X, Ascher-Svanum H, Faries DE, et al. Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy. Clinicoecon Outcomes Res. 2011;379–387.
   Google Scholar
• Rajagopalan K, Trueman D, Crowe L, et al. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia. Pharmacoeconomics. 2016;34(7):709–721.
   PubMed Web of Science ®Google Scholar
• Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, Brewin C, Wing J, editors. Measuring mental health needs (pp. 179–190). London: Gaskell; 1992.
   Google Scholar
• Wagenaar G. Indicateurs et systèmes d’information en santé mentale [Mental Health Indicators and Information Systems]. J Eco Med. 1993;11:201–224. French.
   Google Scholar
• Kay S. Positive–negative symptom assessment in schizophrenia: psychometric issues and scale comparison. Psychiatr Q. 1990;61(3):163–178.
   Google Scholar
• Kay S, Fiszbein A, Opler L. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr Bull. 1987;13(2):261–276.
   PubMed Web of Science ®Google Scholar
• Akaike H. Information theory as an extension of the maximum likelihood principle. In: Petrov B, Csaki F, editors. Second International Symposium on Information Theory. Budapest: Akademiai Kiado; 1973. p. 267–281.
   Google Scholar
• Cavanaugh J. Lecture II: the Akaike Information Criterion. [unpublished PowerPoint slides]. 171:290 Model Selection. Lecture given 28th August. 2012.
   Google Scholar
• Patel R, Jayatilleke N, Broadbent M, et al. Negative symptoms in schizophrenia: a study in a large clinical sample of patients using a novel automated method. BMJ Open. 2015;5(9):e007619.
   PubMed Web of Science ®Google Scholar
• Bobes J, Arango C, Garcia-Garcia M, et al. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry. 2010;71(3):280–286.
   PubMed Web of Science ®Google Scholar
• Remington G, Foussias G, Fervaha G, et al. Treating Negative Symptoms in Schizophrenia: an Update. Curr Treat Options Psychiatry. 2016;3:133–150.
   Google Scholar
• Klingberg S, Wolwer W, Engel C, et al. Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: results of the randomised clinical TONES study. Schizophr Bull. 2011;37(Suppl 2):S98–S110.
   Web of Science ®Google Scholar
• European Commission. Mental Health. Policy. [ citedJan2017]. Available from: https://ec.europa.eu/health/mental_health/policy_en
   Google Scholar
• De HertM, CorrellC, BobesJ, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52–77.
   PubMed Web of Science ®Google Scholar
• BoyerL, FondG, DevictorB, et al. Reflection on the psychiatric financial allocation in France. Encephale. 2016Aug;42(4):379–381.
   Web of Science ®Google Scholar